New hope for lung cancer patients when standard pills fail
NCT ID NCT07181499
First seen Sep 30, 2025 · Last updated Apr 30, 2026 · Updated 25 times
Summary
This study is for people with a common type of advanced lung cancer (non-small cell) that has stopped responding to a class of targeted pills called third-generation EGFR TKIs. Researchers want to see if giving chemotherapy first, followed by a newer targeted drug (befotertinib), can help control the cancer longer. About 28 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Cancer Center of The Fifth Affiliated Hospital of Sun Yat-sen University
RECRUITINGZhuhai, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.